Disclosed are POEGMA-aptamer conjugates with a reduced or eliminated host-immune response. An example conjugate includes an aptamer conjugated to a POEGMA having a plurality of side chains, where each side chain includes 1 to 6 monomers of ethylene glycol repeated in tandem. Also disclosed are methods of making the conjugate and methods of using the conjugate. An example method of use includes a method of controlling coagulation in a subject.
A61K 47/60 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique macromoléculaire, p.ex. une molécule oligomérique, polymérique ou dendrimérique obtenu par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p.ex. polyurées ou polyuréthanes le composé organique macromoléculaire étant un oligomère, un polymère ou un dendrimère de polyoxyalkylène, p.ex. PEG, PPG, PEO ou polyglycérol
A61K 31/7088 - Composés ayant au moins trois nucléosides ou nucléotides
An implantable breast tissue mesh for use in reconstructing breast tissue includes a mesh body having a surrounding edge and at least two mesh extensions extending from the surrounding edge of the mesh body, each mesh extension comprised of mesh having a first end, a second end, and a length therebetween, the first end being integrated into or part of the mesh body. Each mesh extension is configured to be passed through surrounding tissue multiple times to create multiple anchor points with the surrounding tissue upon implantation so as to resist high tension across a breast tissue reconstruction site without dehiscing or migrating.
A61F 2/00 - Filtres implantables dans les vaisseaux sanguins; Prothèses, c.-à-d. éléments de substitution ou de remplacement pour des parties du corps; Appareils pour les assujettir au corps; Dispositifs maintenant le passage ou évitant l'affaissement de structures corporelles tubulaires, p.ex. stents
Disclosed herein are compositions comprising one or more subgenomic Flavivirus RNA (sfRNA) elements and using those compositions in methods of improving mRNA transcript stability, improving mRNA transcript translation efficiency, enhancing gene therapy, and treating and/or preventing a disease or disorder.
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiques; Thérapie génique
Methods and microorganisms for improved malonyl-CoA flux and production of products having malonyl-CoA as a precursor. The methods comprise dynamically regulating, in a stationary phase of a method, a nitrogen regulatory protein. The methods may dynamically regulate more than one gene.
Arizona Board of Regents on Behalf of the University of Arizona (USA)
Duke University (USA)
Inventeur(s)
Rengaswamy, Narayanan
Seshadreesan, Kaushik
Guha, Saikat
Pfister, Henry
Abrégé
A signal comprises a plurality of codewords associated with a set of codewords, each codeword comprising a plurality of symbols associated with a symbol constellation. Processing includes: mapping quantum states associated with symbols of a particular codeword of the signal to a plurality of input qubits, and applying quantum operations to the input qubits according to a quantum circuit for decoding the signal. The quantum operations comprise: controlled unitary multi-qubit operations performed on two or more qubits in a first set of qubits controlled based on two or more qubits in a second set of qubits, an initial quantum measurement performed on an initially measured qubit in the first set of qubits, at least one controlled unitary single-qubit operation performed on a post-measurement state associated with the initially measured qubit, and quantum operations that invert at least a portion of the operations in the plurality of controlled unitary multi-qubit operations.
Disclosed herein are vaccine compositions for the treatment and prevention of urinary tract infections (UT!s) and methods for delivery of the vaccine compositions. Moreover, the disclosure provides adjuvant compositions for vaccines to modulate cellular responses. such as an immune response.
A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p.ex. par les adjuvants chimiques
Rationally-designed LAGLIDADG meganucleases and methods of making such meganucleases are provided. In addition, methods are provided for using the meganucleases to generate recombinant cells and organisms having a desired DNA sequence inserted into a limited number of loci within the genome, as well as methods of gene therapy, for treatment of pathogenic infections, and for in vitro applications in diagnostics and research.
A brain computer interface for interfacing with a brain of a subject is provided. The brain computer interface includes one or more shanks. Each shank includes an array of pixels and output traces. Each pixel includes an electrode and a front-end circuit positioned at a site of the electrode. The front-end circuit is configured to reduce noise in signals recorded by the electrode, and further configured to multiplex the signals. A density of power consumption of the each pixel is equal to or less than 1 μW per area of 50 μm by 50 μm. The output traces are electrically coupled with the array of pixels. A number of output traces is less than a number of pixels in the array due to multiplexing. The one or more shanks are configured to be inserted on and/or into a brain of a subject.
Disclosed herein are compositions for and methods of generating chimeric RNA molecules and methods of treating and/or preventing a genetic disease or disorder using chimeric RNA molecules.
LpxH targeting compounds, compositions thereof, as well as methods for for making and using the same are disclosed herein. The LpxH target compounds typically have a structure pursuant to Formula (I) and/or a salt thereof, wherein Rb is selected from a single bond, C4 to C10 unsubstituted aryl, C4 to C10 substituted aryl, unsubstituted or substituted four to ten member heterocycle ring, C1 to C10 unsubstituted alkyl, and C1 to C10 substituted alkyl; Rc comprises hydrogen, halogen, —OH, —CO2CH3, —COOH, —CN2CF3, —CF3, —C2OH, —CONHOH, —CCOH, C4 to C10 unsubstituted aryl, C4 to C10 substituted aryl, unsubstituted or substituted four to ten member heterocycle ring, C1 to C10 unsubstituted alkyl, or C1 to C10 substituted alkyl; and Rd and Re are independently hydrogen, —OH, —COH, —COH, —COC, —COOH, Rf, or are taken together as an unsubstituted or substituted four to eight member nitrogen containing heterocycle ring.
C07D 209/30 - Indoles; Indoles hydrogénés avec des hétéro-atomes ou avec des atomes de carbone comportant trois liaisons à des hétéro-atomes, avec au plus une liaison à un halogène, liés directement aux atomes de carbone de l'hétérocycle
C07C 311/20 - Sulfonamides ayant des atomes de soufre de groupes sulfonamide liés à des atomes de carbone de cycles aromatiques à six chaînons ayant l'atome d'azote d'au moins un des groupes sulfonamide lié à un atome de carbone d'un cycle autre qu'un cycle aromatique à six chaînons
The present disclosure describes, in part, compositions comprising derivatives and methods of using the same in prevention or treatment of viral infections in a subject.
A method of providing a regional motion display includes receiving a set of temporal images of a target area, generating a set of temporal difference images from the set of temporal images and generating a regional motion display from the set of temporal difference images. The regional motion display includes a representative line through the target area along a y-axis and an x-axis representing time. The method further includes displaying the regional motion display. In some cases, generating the regional motion display includes calculating, for each y-axis pixel, an integral of all pixels along a perpendicular or non-perpendicular line to the target area, a contour along the target area, or a surface of the target area in a temporally corresponding difference image of the set of temporal difference images in a difference image and assigning, for each y-axis pixel, the integral of all pixels as a pixel value.
G06V 10/25 - Détermination d’une région d’intérêt [ROI] ou d’un volume d’intérêt [VOI]
G06V 10/60 - Extraction de caractéristiques d’images ou de vidéos relative aux propriétés luminescentes, p.ex. utilisant un modèle de réflectance ou d’éclairage
G06V 10/75 - Appariement de motifs d’image ou de vidéo; Mesures de proximité dans les espaces de caractéristiques utilisant l’analyse de contexte; Sélection des dictionnaires
13.
Human Cross-Presenting CD141+CLEC9A+ Dendritic Cells, Methods of Producing the Same from Mobilized Peripheral Blood CD34+ Hematopoietic Stem Cells and Methods of Use
The present disclosure describes systems and methods for in vitro differentiation of human cross-presenting CD141+CLEC9A+ dendritic cells from mobilized peripheral blood CD34+ hematopoietic stem cells. The dendritic cells may further comprise an antigen or nucleic acid encoding an antigen. Methods of using the cells are also provided.
The present disclosure provides compositions, systems, and methods related to engineered vascular tissue models. In particular, the present disclosure provides compositions, systems, and methods pertaining to three-dimensional engineered vascular tissue models generated using vascular smooth muscle cells which emulate the structure and functionality of human vasculature.
Technologies for suppressing effects of crosstalk in a quantum circuit of a quantum computing system are disclosed. A pair of target qubits on which to perform a quantum gate operation is selected. The quantum gate operation is performed. A rotation is induced on the target qubits such that crosstalk between any of the target qubits and any of the neighboring qubits in the quantum circuit is canceled out.
The Trustees of Columbia University in the City of New York (USA)
Inventeur(s)
Arepally, Gowthami
Francis, Samuel
Hwu, Christopher
Sames, Dalibor
Sulzer, David
Abrégé
Disclosed herein are methods of diagnosing a disease or condition associated with abnormal platelet activation in a subject. Also disclosed herein are methods for assessing the propensity of donor platelets to release an uptaken fluorescent false neurotransmitter (FFN).
The present disclosure provides compounds according to Formula (I),
The present disclosure provides compounds according to Formula (I),
wherein X, R2, R3, R4, and R5 are defined herein. Further disclosed herein are pharmaceutical compositions, orally administrable dosage forms, and methods for using such compounds in the treatment of various diseases and disorders including inflammation, autoimmune disorders, chronic pain and cancer. In particular embodiments, the present disclosure provides orally bioavailable compounds capable of selectively modulating an activity (e.g., inhibition) of the serine/threonine protein kinase TAK1 and/or related kinases.
C07D 401/06 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une chaîne carbonée contenant uniquement des atomes de carbone aliphatiques
A61P 11/00 - Médicaments pour le traitement des troubles du système respiratoire
A61P 19/02 - Médicaments pour le traitement des troubles du squelette des troubles articulaires, p.ex. arthrites, arthroses
A61P 25/02 - Médicaments pour le traitement des troubles du système nerveux des neuropathies périphériques
18.
Wearable Sensor for Continuous Monitoring of Tissue Mechanics
A wearable device includes an elastically compliant body having a side for attaching to skin of a patient, a plurality of accelerometers for receiving acoustic wave data from acoustic waves transmitted by a transducer, a short-range radio transmitter for transmitting the acoustic wave data to a computing device, a processor for receiving the acoustic wave data from the plurality of accelerometers and providing the acoustic wave data to the short-range radio transmitter, and a battery for providing power to the processor, the plurality of accelerometers, and the short-range radio transmitter. A distance between each accelerometer of the plurality of accelerometers is predetermined. The processor, the plurality of accelerometers, the short-range radio transmitter, and the battery are embedded within the elastically compliant body.
A catheter system with two lumens (e.g., a major lumen and a minor lumen) that can be inserted peripherally into the left heart. The major lumen is used for venting, or blood volume removal, and the minor lumen is used to deliver a treatment substance directly to the left heart. In particular, the minor lumen can be used to deliver an anticoagulation medication directly to the left ventricle. The major lumen can be incorporated into an ECMO system.
Provided herein are compositions and methods for treating cardiac conditions and other diseases. In particular, the disclosure provides compositions and methods for the delivery of sodium channels. The compositions are particularly suitable in gene therapy applications and for cardiac tissue patch implantations.
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiques; Thérapie génique
A61P 9/10 - Médicaments pour le traitement des troubles du système cardiovasculaire des maladies ischémiques ou athéroscléreuses, p.ex. médicaments antiangineux, vasodilatateurs coronariens, médicaments pour le traitement de l'infarctus du myocarde, de la rétinopathie, de l'insuffisance cérébro-vasculaire, de l'artériosclérose rénal
C07K 14/195 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant de bactéries
The disclosure is directed to a G-protein coupled receptor complex. The complex includes (i) a chimeric G protein-coupled receptor (GPCR) comprising a non-native amino acid sequence located within the C-terminus of the GPCR and a synthetic phosphopeptide ligated to the non-native amino acid sequence; and (ii) a β-arrestin (βarr) protein bound to the C-terminus of the GPCR. The disclosure also provides an in vitro method for producing the aforementioned complex, as well as methods for identifying compounds or ligands which bind to and modulate the activity of the complex. Positive allosteric modulators of the β2 adrenergic receptor identified by screening a DNA-encoded library potentiate the activity of β2 agonists and have application in the treatment of obstructive airway disease, bronchospasm, or pre-term labor.
C07K 14/72 - Récepteurs; Antigènes de surface cellulaire; Déterminants de surface cellulaire pour des hormones
C07K 14/47 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
C07K 14/705 - Récepteurs; Antigènes de surface cellulaire; Déterminants de surface cellulaire
G01N 33/68 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des protéines, peptides ou amino-acides
22.
COMPOSITIONS AND METHODS FOR THE GENETIC MANIPULATION OF THE INFLUENZA VIRUS
The present invention provides recombinant viral segments comprising an artificial intron, DNA constructs encoding these viral segments, and recombinant viruses comprising these viral segments. Also provided are methods of making and using the recombinant viruses described herein.
The University of North Carolina at Chapel Hill (USA)
Inventeur(s)
Asokan, Aravind
Mitchell-Dick, Aaron
Murlidharan, Giridhar
Rivera, Ruth Castellanos
Abrégé
The present disclosure provides compositions for and methods of preventing protein aggregation, removing protein aggregates, and improving fluid flux in the brain.
A61K 38/17 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant d'humains
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiques; Thérapie génique
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p.ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
The invention relates to compositions and methods for treating uterine fibroids, wherein a uterine fibroid treatment agent comprising collagenase in an amount effective to cause shrinkage of uterine fibroids is injected or inserted into the uterine fibroid.
Disclosed herein are partially ordered polypeptides, which include a plurality of disordered domains and a plurality of structured domains. The partially ordered polypeptides may have phase transition behavior and form aggregates at, above, or below certain temperatures. Further provided are cellular scaffolds comprised of the partially ordered polypeptides.
A61K 35/12 - Substances provenant de mammifères; Compositions comprenant des tissus ou des cellules non spécifiés; Compositions comprenant des cellules souches non embryonnaires; Cellules génétiquement modifiées
A retinal vessel shadow view optical coherence tomography (RVSV-OCT) image can be created by receiving, at an enhanced OCT processing system, volumetric OCT scan of a patient. The system can segment the volumetric OCT scan to determine layer boundaries and delineate a boundary of interest based on the determined layer boundaries of the segmented volumetric OCT scan. En face vascular information can be extracted to create an RVSV-OCT image by determining a first offset from the boundary of interest and a second offset from the boundary of interest; extracting volumetric data from an area between the first offset and the second offset to create a three-dimensional volume; and identifying a two-dimensional surface from the three-dimensional volume, the two-dimensional surface being the RVSV-OCT image. The RVSV-OCT image can be provided for analysis, for example, to evaluate retinal vascular disease in preterm infants at risk for retinopathy of prematurity.
A61B 3/12 - Appareils pour l'examen optique des yeux; Appareils pour l'examen clinique des yeux du type à mesure objective, c. à d. instruments pour l'examen des yeux indépendamment des perceptions ou des réactions du patient pour examiner le fond de l'œil, p.ex. ophtalmoscopes
A61B 3/00 - Appareils pour l'examen optique des yeux; Appareils pour l'examen clinique des yeux
A61B 3/10 - Appareils pour l'examen optique des yeux; Appareils pour l'examen clinique des yeux du type à mesure objective, c. à d. instruments pour l'examen des yeux indépendamment des perceptions ou des réactions du patient
The present disclosure provides nucleic acid expression cassettes, vectors, compositions and methods for the treatment of ATPase-mediated diseases in a subject.
A61K 38/48 - Hydrolases (3) agissant sur des liaisons peptidiques (3.4)
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiques; Thérapie génique
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p.ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
28.
Cross-Species Compatible Adeno-Associated Virus Compositions and Methods of Use Thereof
The present disclosure provides adeno-associated virus (AAV) vectors, comprising coevolved capsid variant proteins, pharmaceutical compositions, methods of making, and methods for delivering such to a subject.
The present disclosure provides adeno-associated virus (AAV) vectors, comprising coevolved capsid variant proteins, pharmaceutical compositions, methods of making, and methods for delivering such to a subject.
The present disclosure describes, in part, methods of preventing and/or treating cancer in a subject by co-administering an ABL inhibitor and a mevalonate pathway inhibitor.
A61K 31/4439 - Pyridines non condensées; Leurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à cinq chaînons avec l'azote comme hétéro-atome du cycle, p.ex. oméprazole
Disclosed herein are compositions and methods for targeting a novel regulatory element of a gene. The compositions may be used in methods of modifying growth of a cell, decreasing cell fitness, increasing cell fitness, and/or treating cancer such as leukemia.
The present invention relates to fusion proteins and methods of using the same. Specifically, invention relates to fusion proteins comprising an intein and a DNA polymerase, and methods of using the same for DNA synthesis.
Disclosed herein are compositions for and methods of performing a multi-omics assay comprising analyzing chromatin structure and function and analyzing the transcriptome using the same population of cells. Disclosed herein are compositions for and methods of performing a high-throughput chromosome conformation capture on accessible DNA and mRNA-Seq co-assay (HiCAR).
Disclosed herein are compositions and methods of treating a spinal cord injury and improving spinal cord function. Also disclosed are compositions and methods of stimulating regeneration, promoting glial cell proliferation, promoting axonal tract regeneration, triggering neurite outgrowth, and triggering neuron formation in injured and/or damaged spinal cord tissue.
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiques; Thérapie génique
A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
A system and method for imaging or treating a disease in a human or animal body. The system provides to the human or animal body a pharmaceutical carrier including one or more phosphors which are capable of emitting ultraviolet or visible light into the body and which provide x-ray contrast. The system includes one or more devices which infuse a diseased site with a photoactivatable drug and the pharmaceutical carrier, an initiation energy source comprising an x-ray or high energy source which irradiates the diseased site with at least one of x-rays, gamma rays, or electrons to thereby initiate emission of said ultraviolet or visible light into the body, and a processor programmed to at least one of 1) produce images of the diseased site or 2) control a dose of said x-rays, gamma rays, or electrons to the diseased site for production of said ultraviolet or visible light at the diseased site to activate the photoactivatable drug.
A61N 5/06 - Thérapie par radiations utilisant un rayonnement lumineux
A61K 41/17 - Inactivation ou décontamination d'une préparation médicinale avant son administration à un animal ou une personne par lumière ultraviolette [UV] ou infrarouge [IR], rayons X ou rayons gamma
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
A61K 41/00 - Préparations médicinales obtenues par traitement de substances par énergie ondulatoire ou par rayonnement corpusculaire
A61K 49/04 - Préparations de contraste pour rayons X
A61N 5/02 - Thérapie par radiations utilisant des hyperfréquences
A61N 5/10 - Radiothérapie; Traitement aux rayons gamma; Traitement par irradiation de particules
36.
CROSSLINKING COMPOUNDS AND CROSSLINKED ACRYLIC POLYMERIC MATERIALS
Disclosed herein are cyclobutane-based crosslinking compounds that, when incorporated into acrylate-based polymeric materials, can produce toughened acrylate polymer networks. Also disclosed herein are polymers comprising the crosslinkers, methods of preparing toughened polymer networks using the crosslinkers, and methods of using the polymer networks.
C07C 69/757 - Esters d'acides carboxyliques dont un groupe carboxyle est lié à un atome de carbone d'un cycle autre qu'un cycle aromatique à six chaînons dont l'un des groupes OH, O-métal, —CHO, céto, éther, acyloxy, des groupes , des groupes ou des groupes se trouve dans la partie acide
C08F 36/20 - Homopolymères ou copolymères de composés contenant un ou plusieurs radicaux aliphatiques non saturés, l'un au moins contenant plusieurs liaisons doubles carbone-carbone le radical ne contenant que deux doubles liaisons carbone-carbone non conjuguées
C07C 69/753 - Esters d'acides carboxyliques dont un groupe carboxyle est lié à un atome de carbone d'un cycle autre qu'un cycle aromatique à six chaînons d'acides polycycliques
The present disclosure provides compositions and methods for rapid production of chemicals in genetically engineered microorganisms in a large scale. Also provided herein is a high-throughput metabolic engineering platform enabling the rapid optimization of microbial production strains. The platform, which bridges a gap between current in vivo and in vitro bio-production approaches, relies on dynamic minimization of the active metabolic network.
Disclosed herein are CRISPR/Cas systems comprising a fusion protein and at least one gRNA targeting a gene or a regulatory element thereof in a cell such as an immune cell, and vector compositions encoding the same. The systems and compositions may be used in methods of modulating expression of a gene in a cell such as an immune cell, as well as in methods of treating a disease such as cancer, autoimmune diseases, or viral infections.
C07K 14/47 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
C12N 15/90 - Introduction stable d'ADN étranger dans le chromosome
42.
SELF-REPAIRING BIOMIMETIC LUBRICANTS AND METHODS OF MAKING AND USING SAME
A61K 47/54 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique
C08B 37/08 - Chitine; Sulfate de chondroïtine; Acide hyaluronique; Leurs dérivés
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p.ex. composés antiphlogistiques et pour le cœur
Provided herein is an antigen display library for detecting antibodies produced by an individual; and methods of using the antigen display library to generate an antibody signature, the method comprising contacting a biological sample containing antibodies from an individual with the antigen display library, isolating phage clones displaying antigenic epitopes recognized by antibody in the sample, and identifying the antigenic epitopes that were recognized by antibody in the sample. Also provided are kits for generating an antibody signature comprising the antigen display library, a substrate for isolating phage clones bound by antibody, and may further comprise reagents useful for generating the antibody signature.
Provided herein are compositions and methods for detection of N6-methyladenosine (m6A) in ribonucleic acid (RNA). The provided compositions include fusion proteins that can be used to edit RNA and detect m6A residues. Also provided are nucleic acids, vectors, constructs, host cells, and transgenic animals that encode or express such fusions proteins.
In various embodiments, the present invention relates to a series of biodegradable thiol-yne elastoners that incorporate degradable C4-C14 dicarboxylic acid-based monomer units made using a nucleophilic thiol-yne polymerization methodology that targets high cis-content at comparable molar masses to provide excellent mechanical properties. As each C4-C14 dicarboxylic acid-based monomer unit contains at least two labile ester linkages, altering the stoichiometry of degradable C4-C14 dicarboxylic acid-based monomer unit incorporation allows the degradation rate of the material to be tuned precisely, while retaining control over the mechanical properties by maintaining the cis/frans stereochemistry of the double bonds to provide independent tuning of mechanical and degradative properties. In one or more embodiments, these degradable C4-C14 dicarboxylic acid-based monomers can be introduced into the thiol-yne polymerization reaction via one, or both, of the thiol and alkyne functional groups, providing additional flexibility in developing suitable polymer species.
Aspects of the present disclosure describe techniques for using a parabolic Cassegrain-type reflector for ablation. For example, a system for ablation loading of a trap is described that includes a reflector having a hole aligned with a loading aperture of the trap, and an atomic source positioned at a focal point of the reflector, where one or more laser beams are reflected from a reflective front side of the reflector and focused on a surface of the atomic source to produce an atomic plume, and the atomic plume once produced passing through the hole in the reflector and through a loading aperture of the trap for loading the trap. A method for ablation loading of a trap within a chamber in a trapped ion system is also described.
Provided herein is an antigen display library for detecting antibodies produced by an individual; and methods of using the antigen display library to generate an antibody signature, the method comprising contacting a biological sample containing antibodies from an individual with the antigen display library, isolating phage clones displaying antigenic epitopes recognized by antibody in the sample, and identifying the antigenic epitopes that were recognized by antibody in the sample. Also provided are kits for generating an antibody signature comprising the antigen display library, a substrate for isolating phage clones bound by antibody, and may further comprise reagents useful for generating the antibody signature.
Disclosed herein are compositions and methods for treating a subject having an itch-related disorder, such as dermatological disorders or systemic disorders comprising itch. The methods may include determining the level of a biomarker in a biological sample from the subject. The biomarker may be selected from TRPV4 expression, lysophosphatidylcholine, and miRNA-146a expression, or a combination thereof. The subject may be identified as having the itch-related disorder when the level of the biomarker is greater in a sample from the subject than in a control. An anti-pruritic therapy may be administered to treat the subject having the itch-related disorder.
C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p.ex. oligonucléotides anti-sens
G01N 33/68 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des protéines, peptides ou amino-acides
The present disclosure describes, in part, a polymer, for example a thermoplastic polyurethane elastomer, comprising one or more subunits comprising (i) at least one dianhydrohexitole moiety (ii) at least one urethane moiety and (ill) a thiol moiety having two or more sulphur atoms. The thermoplastic polyurethane elastomers may be biodegradable and possess excellent thermoplastic properties, including outstanding toughness, resulting from its semi-crystallinity and low glass transition temperature, that surpasses many leading plastics such as nylon 6 and high-density polyethylene (HOPE) and methods of making same.
An apparatus for guiding the migration of cancer and other cells includes a reservoir device, a cover, a tube, a nanofiber structure, and a lock device. The reservoir device defines a reservoir having an open top. The cover is configured for removable installation over the open top of the reservoir. The tube has a proximal end portion reaching into the reservoir. The nanofiber structure communicates an inlet port in the tube with the reservoir. The lock device interlocks the tube with the reservoir device, and also interlocks the nanofiber structure with the reservoir device.
B82Y 15/00 - Nanotechnologie pour l’interaction, la détection ou l'actionnement, p.ex. points quantiques comme marqueurs en dosages protéiques ou moteurs moléculaires
B82Y 5/00 - Nanobiotechnologie ou nanomédecine, p.ex. génie protéique ou administration de médicaments
A61M 25/02 - Dispositifs de maintien en position, p.ex. sur le corps
51.
EFFICIENT MOTIONAL-MODE CHARACTERIZATION FOR HIGH-FIDELITY TRAPPED-ION QUANTUM COMPUTING
A method of using an ion trap quantum computer includes performing a first measurement of bright-state population of each ion in an ion chain, the each ion coupled to one of motional modes of the ion chain, while varying laser coupling frequency, computing mode frequency of the one of the motional mode based on the measured bright-state population in the first measurement, performing a second measurement of bright-state population of each ion in the ion chain, and computing coupling strength of the each ion and the one of the motional mode by fitting the bright-state population of the each ion measured in the second measurement to a value of the bright-state population computed based on the computed mode frequency of the one of the motional modes and non-zero temperature effect of the motional modes.
G06N 10/40 - Réalisations ou architectures physiques de processeurs ou de composants quantiques pour la manipulation de qubits, p.ex. couplage ou commande de qubit
G06N 10/60 - Algorithmes quantiques, p.ex. fondés sur l'optimisation quantique ou les transformées quantiques de Fourier ou de Hadamard
A thermoacoustic measurement probe includes an open-ended hollow radio-frequency (RF) waveguide; at least two RF feeds positioned within the open-ended hollow RF waveguide, wherein each RF feed is configured to provide RF energy; and a thermoacoustic transducer, wherein the open-ended hollow RF waveguide, in the form of a sleeve, surrounds and is mechanically joined to the thermoacoustic transducer.
G01N 29/06 - Visualisation de l'intérieur, p.ex. microscopie acoustique
G02F 1/225 - Dispositifs ou dispositions pour la commande de l'intensité, de la couleur, de la phase, de la polarisation ou de la direction de la lumière arrivant d'une source lumineuse indépendante, p.ex. commutation, ouverture de porte ou modulation; Optique non linéaire pour la commande de l'intensité, de la phase, de la polarisation ou de la couleur par interférence dans une structure de guide d'ondes optique
A method of object detection in paired imaging includes detecting areas of interest for each image of a set of multi-view images, each detected area of interest having a corresponding initial probability of being an area of interest; determining a matching probability for each detected area of interest across the set of multi-view images such that detected areas of interest from one image of the set of multi-view images are assigned matching probabilities with respect to detected areas of interest of other images of the set of multi-view images; generating a modified probability for each detected area of interest according to one or more object-specific weighting factors and one or more of the matching probabilities for that detected area of interest; adjusting the initial probability of each detected area of interest using the modified probability to generate a refined probability for each detected area of interest; and identifying the detected areas of interest in each image that have refined probabilities that meet a minimum threshold probability.
The present disclosure provides systems and methods relating to the treatment of gastrointestinal dysmotility. In particular, the present disclosure provides systems and methods for delivering temporal patterns of electrical stimulation with respect to a refractory period to either suppress (e.g., treat hypermotility) or stimulate (e.g., treat hypomotility) contractions and motility in the gastrointestinal tract of a subject.
A61N 1/36 - Application de courants électriques par électrodes de contact courants alternatifs ou intermittents pour stimuler, p.ex. stimulateurs cardiaques
55.
METHOD OF TREATING CANCER USING SELECTIVE ESTROGEN RECEPTOR MODULATORS
Disclosed herein are methods of treating subjects suffering from estrogen receptor positive cancer of the brain by administering a selective estrogen receptor degrader (SERM). Also disclosed are methods of treating a cancer that is resistant to an estrogen receptor modulator by administering a SERM.
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 31/136 - Amines, p.ex. amantadine ayant des cycles aromatiques, p.ex. méthadone ayant le groupe amino lié directement au cycle aromatique, p.ex. benzène-amine
A61K 31/40 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines ayant des cycles à cinq chaînons avec un azote comme seul hétéro-atome d'un cycle, p.ex. sulpiride, succinimide, tolmétine, buflomédil
A61K 31/4535 - Pipéridines non condensées, p.ex. pipérocaïne contenant d'autres systèmes hétérocycliques contenant un hétérocycle avec le soufre comme hétéro-atome du cycle, p.ex. pizotifène
A61K 31/565 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrène; Leurs dérivés, p.ex. stéroïdes non substitués en position 17 bêta par un atome de carbone, p.ex. œstrane, œstradiol
A61K 31/5685 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrène; Leurs dérivés, p.ex. stéroïdes non substitués en position 17 bêta par un atome de carbone, p.ex. œstrane, œstradiol substitués en positions 10 et 13 par une chaîne ayant au moins un atome de carbone, p.ex. androstane, testostérone ayant un groupe oxo en position 17, p.ex. androstérone
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p.ex. composés antiphlogistiques et pour le cœur
C07C 217/78 - Composés contenant des groupes amino et hydroxy éthérifiés liés au même squelette carboné ayant des groupes amino et des groupes hydroxy éthérifiés liés à des atomes de carbone de cycles aromatiques à six chaînons du même squelette carboné
C07C 217/84 - Composés contenant des groupes amino et hydroxy éthérifiés liés au même squelette carboné ayant des groupes amino et des groupes hydroxy éthérifiés liés à des atomes de carbone de cycles aromatiques à six chaînons du même squelette carboné ayant des groupes amino et des groupes hydroxy éthérifiés liés à des atomes de carbone de cycles aromatiques à six chaînons non condensés du même cycle aromatique à six chaînons non condensé l'atome d'oxygène d'au moins un des groupes hydroxy éthérifiés étant lié de plus à un atome de carbone acyclique
56.
Compositions and Methods Relating to Alzheimer's Disease
Disclosed herein are methods of administering precision gene therapy, treating and/or preventing Alzheimer' disease progression, and reducing expression of APOE and APOE e4. Disclosed herein are isolated nucleic acid molecules, viral vectors, lentiviral vectors, pharmaceutical formulations, host cells, guide RNAs and plasmids for use in the disclosed methods.
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p.ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
57.
REPLICATION INCOMPETENT INFLUENZA VACCINE PLATFORM FOR FOREIGN PROTEIN DELIVERY
The present invention provides replication incompetent influenza viral particles comprising a modified hemagglutinin (HA) protein. Also provided are methods for making and using the viral particles, and cell lines for making the viral particles.
Disclosed herein are therapeutic targets for the correction of the human dystrophin gene by gene editing and methods of use. The compositions and methods may include gRNAs targeting exons 44 and 55. The compositions and methods may also Include a mutant inverted terminal repeat (ITR) to generate a self-complementary vector genome.
C12N 15/90 - Introduction stable d'ADN étranger dans le chromosome
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiques; Thérapie génique
59.
CRISPR/CAS-BASED BASE EDITING COMPOSITION FOR RESTORING DYSTROPHIN FUNCTION
The invention is directed to modified HIV-1 envelopes, compositions comprising these modified envelopes, nucleic acids encoding these modified envelopes, compositions comprising these nucleic acids, and methods of using these modified HIV-1 envelopes and/or these nucleic acids to induce immune responses.
The present invention provides compositions and methods using one or more strains of Akkermansia muciniphila. Particularly, the compositions comprising one or more A. muciniphila strains may be used to add in reduction in obesity and in methods of recolonizing the flora of the gut of a subject, as described in the disclosure.
Disclosed herein are compositions and methods for inhibiting a gene selected from OGDH, LIPT1, SDHC, and DHRS7B. The inhibitors may be used to activate SNRPN, SPA1, SPA2, or SNORD118, or a combination thereof. The inhibitors may also be used to treat a subject having Prader Willi Syndrome (PWS) or a PWS-like disorder.
In various embodiments, the present invention relates to a series of anti-fouling zwitterionic biodegradable thiol-yne elastomers that incorporate degradable C4-C14 dicarboxylic acid-based monomer units made using a nucleophilic thiol-yne polymerization methodology that targets high cis-content at comparable molar masses to provide excellent mechanical properties and zwitterionic side chains that provide anti fouling properties. As each C4-C14 dicarboxylic acid-based monomer unit contains at least two labile ester linkages, altering the stoichiometry of degradable C4-C14 dicarboxylic acid-based monomer unit incorporation allows the degradation rate of the material to be tuned precisely, while retaining control over the mechanical properties by maintaining the cis/trans stereochemistry of the double bonds to provide independent tuning of mechanical and degradative properties.
Cellulose-reinforced hydrogels may include a cellulose nanofiber network and an interstitial hydrogel portion within interstitial regions of the cellulose nanofiber network, the interstitial hydrogel portion comprising polyvinyl alcohol (PVA), wherein the hydrogel component has a crystallinity of 20% or greater.
A61L 27/48 - Matériaux composites, c. à d. en couches ou contenant un matériau dispersé dans une matrice constituée d'un matériau analogue ou différent comportant une matrice macromoléculaire avec des charges macromoléculaires
An apparatus for guiding the migration of cancer and other cells includes a reservoir device, a cover, a tube, a nanofiber structure, and a lock device. The reservoir device defines a reservoir having an open top. The cover is configured for removable installation over the open top of the reservoir. The tube has a proximal end portion reaching into the reservoir. The nanofiber structure communicates an inlet port in the tube with the reservoir. The lock device interlocks the tube with the reservoir device, and also interlocks the nanofiber structure with the reservoir device.
B82Y 15/00 - Nanotechnologie pour l’interaction, la détection ou l'actionnement, p.ex. points quantiques comme marqueurs en dosages protéiques ou moteurs moléculaires
B82Y 5/00 - Nanobiotechnologie ou nanomédecine, p.ex. génie protéique ou administration de médicaments
A61M 25/02 - Dispositifs de maintien en position, p.ex. sur le corps
66.
METHODS FOR IDENTIFICATION, STRATIFICATION, AND TREATMENT OF CNS DISEASES
Described herein are methods for identifying mitochondrial defects using metabolomics and genetic analyses and using this information to stratify patients and to correct for metabolic defects in a precision medicine approach. One embodiment is a method for isolating and analyzing samples containing one or more mitochondrial biomarker metabolites or genetic markers useful for the analysis, identification, stratification or classification, and treatment of metabolic changes associated with a CNS or neuropsychiatric disease in a subject and therapies useful for the treatment thereof. In one aspect, the biomarker metabolites comprise mitochondrial metabolites including acylcarnitines and endocannabinoids and the genetic analyses focus on metabolic enzymes or transport mechanisms.
G01N 33/68 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des protéines, peptides ou amino-acides
C12Q 1/6883 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p.ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p.ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p.ex. composés antiphlogistiques et pour le cœur
G01N 33/53 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet
G01N 33/92 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des lipides, p.ex. le cholestérol
67.
INTRAVASCULAR MEMBRANE OXYGENATOR CATHETER WITH OSCILLATING HOLLOW FIBER MEMBRANES
The present disclosure describes intravascular oxygenation systems and methods with one or more of improved oxygen diffusion flux, improved resistance to bubble formation on the surface of non-porous hollow fibers, and reduced size. The systems and methods include a pneumatic inlet coupled to a pneumatic source that provides a gas containing oxygen at a high pressure. A plurality of hollow fiber membranes (HFM) are in pneumatic communication with the pneumatic inlet to receive the gas containing oxygen and with an outlet to exhaust a partially deoxygenated gas. An electronic controller drives the motor to oscillate the plurality of HFMs to cause a diffusive flux of the gas containing oxygen from the plurality of HFMs into a region of interest of a subject. The electronic controller may drive the motor according to an oscillation pattern, which may include a macro-oscillation with superimposed micro-oscillations.
A device for accessing a cavity includes a tube and a trocar. The trocar extends through the tube and includes a handle, a sheath, and a tip member. The sheath is opposite the handle. The tip member is disposed in the sheath. The tip member is biased in an extension direction away from the handle. The tip member also includes an indicator indicating a position of the tip member relative to the handle.
Method and apparatuses for forming gel droplets including biological tissue (e.g., cells), and in particular, methods and apparatuses for removing oil from the gel droplets comprising dissociated cells (including micro-organospheres) are described herein. Although it is beneficial to use oil in the formation of these gel droplets, and particularly micro-organospheres, oil may inhibit growth and survival of the cells within the gel droplets. The methods and apparatuses described herein may permit the removal of oil and may enhance survival and quality of the resulting gel droplets.
C12M 1/00 - Appareillage pour l'enzymologie ou la microbiologie
C12M 3/06 - Appareillage pour la culture de tissus, de cellules humaines, animales ou végétales, ou de virus avec des moyens de filtration, d'ultrafiltration, d'osmose inverse ou de dialyse
B01D 69/02 - Membranes semi-perméables destinées aux procédés ou aux appareils de séparation, caractérisées par leur forme, leur structure ou leurs propriétés; Procédés spécialement adaptés à leur fabrication caractérisées par leurs propriétés
B01D 15/38 - Adsorption sélective, p.ex. chromatographie caractérisée par le mécanisme de séparation impliquant une interaction spécifique non couverte par un ou plusieurs des groupes , p.ex. chromatographie d'affinité, chromatographie d'échange par ligand ou chromatographie chirale
70.
SYSTEM AND METHOD FOR LARGE FIELD OF VIEW, SINGLE CELL ANALYSIS
A method and system for medical imaging employs an excitation source configured to cause an object having a plurality of cells to at least one of emit, reflect, and fluoresce light. An optical receptor is employed that is configured to receive the light from the object. A filter assembly receives the light from the optical receptor and filters the light. An image processor having a field of view (FOV) substantially greater than a diameter of a cell of the object and an analysis resolution substantially matched to the diameter of a cell of the object that receives the filtered light from the filter and analyzes the filtered light corresponding to each cell in the FOV. A feedback system is provided that is configured to provide an indication of a state of each cell in the FOV and a location of a cell in the FOV meeting a predetermined condition.
There are no FDA-approved disease-modifying therapies for GSDs like GSD Ia and GSD Ib. Disclosed herein are compositions for and methods of detecting GSD biomarkers as well as methods of diagnosing GSD, methods of determining the efficacy of a GSD treatment, methods of monitoring metabolic control status, and methods of determining the efficacy of regulating dietary intake of carbohydrates using the disclosed biomarkers.
G01N 33/66 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir les sucres du sang, p.ex. le galactose
72.
COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS
The present disclosure describes, in part, compositions and methods for the treatment of neurological disorders using an ATM inhibitor. The methods are useful for the increased treatment of subjects that express a mutant Leucine Rich Repeat Kinase 2 (LRRK2) having kinase activity as compared to the wild type LRRK2. Exemplary LRRK2 mutations include G2019S, R1441C, R1441G, R1441H, Y1699C, or I2020T.
A61K 31/5377 - 1,4-Oxazines, p.ex. morpholine non condensées et contenant d'autres hétérocycles, p.ex. timolol
A61K 31/4745 - Quinoléines; Isoquinoléines condensées en ortho ou en péri avec des systèmes hétérocycliques condensées avec des systèmes cycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. phénanthrolines
C12Q 1/6883 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p.ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p.ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p.ex. composés antiphlogistiques et pour le cœur
73.
Methods, systems, and computer readable media for conducting an automatic assessment of postural control of a subject
The subject matter described herein includes methods, systems, and computer readable media for conducting an automatic assessment of postural control of a subject. According to one aspect, a method occurs at a computing platform including a processor and memory. The method includes displaying a stimulus to which a subject responds, capturing facial image data of the subject, analyzing the facial image data to determine a frequency of head displacement information associated with the subject, using the head displacement information to derive postural control assessment data, and determining that the postural control assessment data is indicative of a neurodevelopmental or neuropsychiatric disorder associated with the subject.
G06T 7/70 - Détermination de la position ou de l'orientation des objets ou des caméras
A61B 5/11 - Mesure du mouvement du corps entier ou de parties de celui-ci, p.ex. tremblement de la tête ou des mains ou mobilité d'un membre
G06F 3/01 - Dispositions d'entrée ou dispositions d'entrée et de sortie combinées pour l'interaction entre l'utilisateur et le calculateur
G16H 50/20 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicales; TIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le diagnostic assisté par ordinateur, p.ex. basé sur des systèmes experts médicaux
G16H 50/30 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicales; TIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour l’évaluation des risques pour la santé d’une personne
Compositions and methods of promoting myelination in neurons are disclosed. The compositions include factors present in an umbilical cord blood derived macrophage cell population culture medium which can promote maturation of oligodendrocytes to promote myelination of neurons. Clinal and non-clinical uses of the compositions are also disclosed.
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p.ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
According to various embodiments, systems and methods for spatial sampling in proximity to the Nyquist limit in traveling-wave antenna systems are disclosed. An apparatus can include a traveling-wave antenna array comprising a plurality of adjacent traveling-wave antennas that each include a plurality of tunable elements that are spaced at, near, or above a Nyquist limit spacing to form an array of tunable elements. The apparatus also includes a phase diversity feed coupled to the traveling-wave antenna array that is configured to provide input to the traveling-wave antenna array including phase diverse input to two or more of the plurality of adjacent traveling-wave antennas. Further, the apparatus includes a plurality of grayscale tuning elements configured to tune the plurality of tunable elements along one or more ranges of one or more tuning variables to form one or more specific output radiation patterns through the traveling-wave antenna array based on the input.
H01Q 11/02 - Antennes non résonnantes, p.ex. antennes à onde progressive
H01Q 1/38 - Forme structurale pour éléments rayonnants, p.ex. cône, spirale, parapluie formés par une couche conductrice sur un support isolant
H01Q 21/08 - Réseaux d'unités d'antennes, de même polarisation, excitées individuellement et espacées entre elles les unités étant espacées le long du trajet rectiligne ou adjacent à celui-ci
H01Q 13/20 - Antennes constituées par un guide non résonnant à ondes de fuite ou une ligne de transmission; Structures équivalentes produisant un rayonnement le long du trajet de l'onde guidée
76.
PURIFICATION MATRICES COMPRISING AAV-BINDING POLYPEPTIDES AND METHODS OF USING THE SAME
Disclosed herein are vectors compositions for gene editing of muscle-specific stem cells, or satellite cells, in vivo and methods for treating Duchenne Muscular Dystrophy.
An apparatus includes a traveling-wave antenna array comprising a plurality of adjacent metamaterial surface antennas comprising a waveguide or a cavity, each adjacent metamaterial surface antenna comprising an array of metamaterial radiators coupled to a surface of the waveguide or the cavity, each metamaterial radiator comprising an individually addressable tunable component that can be tuned over a spectral bandwidth to generate different radiation patterns. The apparatus further includes a phase diversity feed coupled to the traveling-wave antenna array and configured to provide adjustable phase diverse input to two or more of the plurality of adjacent metamaterial surface antennas, the phase diverse input comprising a first phase for a first traveling-wave antenna and a second phase for a second traveling-wave antenna, the first phase being different from the second phase, wherein the phase diverse input is-selected to suppress grating lobes for a directed beam pattern selected for transmission.
H01Q 13/20 - Antennes constituées par un guide non résonnant à ondes de fuite ou une ligne de transmission; Structures équivalentes produisant un rayonnement le long du trajet de l'onde guidée
79.
A HIGH-THROUGHPUT SCREENING METHOD TO DISCOVER OPTIMAL GRNA PAIRS FOR CRISPR-MEDIATED EXON DELETION
Disclosed herein are methods of using probes for high-throughput screening of guide RNA (gRNA) efficiency for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRiSPR-associated (Cas)-based genome editing systems. Further disclosed herein is a humanized transgenic mouse model that recapitulates the severe DMD pathology of human patients. The mouse model may be used for determining the feasibility of CRISPR-based therapies for the correction of the human dystrophin gene by gene editing and methods of use.
G01N 33/50 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique
C12N 15/11 - Fragments d'ADN ou d'ARN; Leurs formes modifiées
C12N 15/10 - Procédés pour l'isolement, la préparation ou la purification d'ADN ou d'ARN
C12N 15/90 - Introduction stable d'ADN étranger dans le chromosome
C12N 15/85 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes pour cellules animales
C07K 14/47 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
B01L 3/00 - Récipients ou ustensiles pour laboratoires, p.ex. verrerie de laboratoire; Compte-gouttes
G01N 33/543 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet avec un support insoluble pour l'immobilisation de composés immunochimiques
81.
COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING A DYSTONIA
Disclosed herein are compositions, kits, and methods for identifying protein or miRNA biomarkers for dystonia, for treating a subject having a dystonia, for predicting penetrance of a dystonia in a subject, and for predicting responsiveness to a dystonia treatment.
C12Q 1/6883 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p.ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique
G01N 33/68 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des protéines, peptides ou amino-acides
A61K 31/427 - Thiazoles non condensés et contenant d'autres hétérocycles
82.
THROMBUS IMAGING APTAMERS AND METHODS OF USING SAME
Provided herein are imaging agents, antidotes to the imaging agents and methods of using the same to image a thrombus or blood clot or thrombin including sites of thrombin accumulation and to diagnose and treat thrombosis. The imaging agents include an aptamer capable of binding the thrombus or thrombin in particular linked to a reporter moiety. The imaging agents may be used to label the thrombus or sites of thrombin accumulation. Antidotes capable of binding to the aptamer in the imaging agent are also provided. The antidotes may further be linked to a quencher capable of quenching the reporter moiety.
C07H 21/02 - Composés contenant au moins deux unités mononucléotide comportant chacune des groupes phosphate ou polyphosphate distincts liés aux radicaux saccharide des groupes nucléoside, p.ex. acides nucléiques avec le ribosyle comme radical saccharide
C12N 15/115 - Aptamères, c. à d. acides nucléiques liant spécifiquement une molécule cible avec une haute affinité sans s'y hybrider
A method includes receiving, by a mobile computing device from an electroencephalogram (EEG) monitoring headset, an incoming wireless communication signal including an EEG data stream. The method may further include processing, by an application running on the mobile computing device, the received EEG data stream to determine at least one actionable command for at least one peripheral device. The method may also include transmitting, by the mobile computing device to the at least one peripheral device, at least one outgoing wireless communication signal including the at least one determined actionable command.
G05B 19/4155 - Commande numérique (CN), c.à d. machines fonctionnant automatiquement, en particulier machines-outils, p.ex. dans un milieu de fabrication industriel, afin d'effectuer un positionnement, un mouvement ou des actions coordonnées au moyen de données d'u caractérisée par le déroulement du programme, c.à d. le déroulement d'un programme de pièce ou le déroulement d'une fonction machine, p.ex. choix d'un programme
G06F 3/01 - Dispositions d'entrée ou dispositions d'entrée et de sortie combinées pour l'interaction entre l'utilisateur et le calculateur
Disclosed herein are lateral flow devices that can sensitively detect an analyte in a sample by using two different populations of nanoparticles. An example device comprises a porous substrate, the porous substrate comprising a sample zone, the sample zone including a detection nanoparticle and a control nanoparticle, wherein the detection nanoparticle and the control nanoparticle each include a different detection label; and a detection zone, the detection zone including a test line and a control line downstream from the test line. Also disclosed are methods and kits including the devices.
G01N 33/569 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet pour micro-organismes, p.ex. protozoaires, bactéries, virus
G01N 33/543 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet avec un support insoluble pour l'immobilisation de composés immunochimiques
85.
SARS-2 SPIKE PROTEIN DESIGNS, COMPOSITIONS AND METHODS FOR THEIR USE
Described herein are hydrogels attached to a base with the strength and fatigue comparable to that of cartilage on bone and methods of forming them. The methods and apparatuses described herein may achieve an attachment strength between a hydrogel and a substrate equivalent to the osteochondral junction. In some examples the hydrogel may be a triple-network hydrogel (such as BC-PVA-PAMPS) that is attached to a porous substrate (e.g., a titanium base) with the shear strength and fatigue strength equivalent to that of the osteochondral junction.
A61L 27/32 - Matériaux contenant du phosphore, p.ex. apatite
A61L 27/36 - Matériaux pour prothèses ou pour revêtement de prothèses contenant des constituants de constitution indéterminée ou leurs produits réactionnels
Disclosed herein are optimized guide RNAs (gRNAs) and methods of designing and using said optimized gRNAs that have increased target binding specificity and reduced off-target binding.
An imaging system for performing a hybrid spiral scan pattern includes a scanner, a scanner controller in communication with the scanner to direct the scanner to perform a hybrid spiral scan pattern, wherein the hybrid spiral scan pattern includes a constant angular velocity (CAV) spiral scan pattern, a constant linear velocity (CLV) spiral scan pattern, and a transition spiral scan pattern. In some cases, the imaging system further includes a light source, and the scanner is positioned to receive light from the light source and direct the light to an object. In some cases, the imaging system further includes at least one position sensor for detecting actual positions of the scanner during the hybrid spiral scan pattern. In some cases, the imaging system further includes an image processor coupled to receive position data detected by the at least one position sensor and produce an image.
The present invention relates to a distinct B cell subset, B10 cells, that regulate T cell mediated inflammatory responses through the secretion of interleukin-10 (IL-10). The invention also relates to the use of B10 cells in the manipulation of immune and inflammatory responses, and in the treatment of disease. Therapeutic approaches involving adoptive transfer of B10 cells, or expansion of their endogenous levels for controlling autoimmune or inflammatory diseases and conditions are described. Ablation of B10 cells, or inhibition of their IL-10 production can be used to upregulate immunodeficient conditions, ameliorate infectious diseases and/or to treat tumors/cancer. Diagnostic applications are also encompassed.
C07K 16/28 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
A61K 35/17 - Lymphocytes; Lymphocytes B; Lymphocytes T; Cellules tueuses naturelles; Lymphocytes activés par un interféron ou une cytokine
G01N 33/50 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique
G01N 33/68 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des protéines, peptides ou amino-acides
91.
TECHNOLOGIES FOR PARTICLE MANIPULATION USING HARMONIC ACOUSTIC WAVES
Technologies for harmonic acoustic manipulation of colloidal particles include a system having a piezoelectric substrate coupled to one or more segmented acoustic transducers and a fluid positioned above the substrate. The segmented transducers have multiple segments, each with a resonant frequency equal to a harmonic frequency. The system further includes a controller that generates a harmonic signal including multiple harmonic components and applies the signal to the segmented acoustic transducers to generate an acoustic potential field in the fluid and manipulate the colloidal particles. The system may translate or rotate the particles, and may form the particles into a colloidal crystal monolayer. The system may selectively pair or otherwise group and separate individual particles. The system may pair and separate multiple groups of particles. The system may measure adhesion between particles. The system may pattern particles over a surface. The colloidal particles may be cells.
Aspects of the present disclosure relate generally to systems and methods for use in the implementation and/or operation of quantum information processing (QIP) systems, and more particularly, to methods and systems for improving vacuum in compact room temperature packages. An exemplary method for preparing a vacuum chamber for a QIP system includes inserting, into a processing vacuum chamber, a lid having a shadow mask on an optical window, coating the inside of the lid with a getter material; removing the shadow mask from the optical window; and providing an ion trap package in the processing vacuum chamber and welding the lid on a top of the ion trap package to prepare the vacuum chamber.
G06N 10/40 - Réalisations ou architectures physiques de processeurs ou de composants quantiques pour la manipulation de qubits, p.ex. couplage ou commande de qubit
93.
ENGINEERED INFLUENZA POLYNUCLEOTIDES, VIRUSES, VACCINES AND METHODS OF MAKING AND USING THE SAME
Engineered Influenza polynucleotides, viruses, vaccines, and methods of making and using the same are provided. More specifically, the present inventors have developed replication competent engineered influenza viruses having, for example, a modified segment 4 and/or segment 6 that include at least one additional polynucleotide encoding a heterologous polypeptide.
A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p.ex. par les adjuvants chimiques
C12N 9/24 - Hydrolases (3.) agissant sur les composés glycosyliques (3.2)
94.
SYSTEMS AND METHODS FOR PREDICTION AND DESIGN OF NEURAL STIMULATION
The present disclosure describes novel systems and methods to estimate the response of neurons to electrical stimulation and to determine the optimal electrode geometry and parameters of stimulation to activate or block specific targeted groups of neurons without activation or block of non-targeted groups of neurons.
A61N 1/36 - Application de courants électriques par électrodes de contact courants alternatifs ou intermittents pour stimuler, p.ex. stimulateurs cardiaques
G06N 3/0442 - Réseaux récurrents, p.ex. réseaux de Hopfield caractérisés par la présence de mémoire ou de portes, p.ex. mémoire longue à court terme [LSTM] ou unités récurrentes à porte [GRU]
G06N 3/084 - Rétropropagation, p.ex. suivant l’algorithme du gradient
95.
Methods and Compositions for the Treatment of Steatosis-Associated Disorders
The present disclosure is directed to methods of treating a steatosis-associated disorder by administering a therapeutic agent selected from a lysosomal enzyme, an autophagy-inducing agent, or a combination thereof. Steatosis-associated disorders discussed herein include GSD Ia, GSD Ib, GSD Ic, NAFLD, and NASH. Other embodiments are directed to methods of reversing steatosis, modulating autophagy, inducing autophagy, and reversing glycogen storage.
A61K 31/436 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à six chaînons ayant l'oxygène comme hétéro-atome du cycle, p.ex. rapamycine
A61K 31/216 - Esters, p.ex. nitroglycérine, sélénocyanates d'acides carboxyliques d'acides ayant des cycles aromatiques, p.ex. bénactizyne, clofibrate
A61K 31/352 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p.ex. fungichromine ayant des cycles à six chaînons avec un oxygène comme seul hétéro-atome d'un cycle condensés avec des carbocycles, p.ex. cannabinols, méthanthéline
A61K 31/167 - Amides, p.ex. acides hydroxamiques ayant des cycles aromatiques, p.ex. colchicine, aténolol, progabide ayant l'atome d'azote d'un groupe carboxamide lié directement au cycle aromatique, p.ex. lidocaïne, paracétamol
A61P 3/00 - Médicaments pour le traitement des troubles du métabolisme
A61K 31/277 - Nitriles; Isonitriles ayant un cycle, p.ex. vérapamil
A61K 31/385 - Composés hétérocycliques ayant le soufre comme hétéro-atome d'un cycle ayant plusieurs atomes de soufre dans le même cycle
A61K 31/5415 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec au moins un azote et au moins un soufre comme hétéro-atomes d'un cycle, p.ex. sulthiame condensés en ortho ou en péri avec des systèmes carbocycliques, p.ex. phénothiazine, chlorpromazine, piroxicam
A61K 31/55 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines ayant des cycles à sept chaînons, p.ex. azélastine, pentylènetétrazole
A61K 31/575 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrène; Leurs dérivés, p.ex. stéroïdes substitués en position 17 bêta par une chaîne d'au moins trois atomes de carbone, p.ex. cholane, cholestane, ergostérol, sitostérol
An integrated circuit (IC) protection circuit can include a reconfigurable block that receives a seed value from a tamper-proof memory and generates a dynamic key; an authentication block that receives the dynamic key from the reconfigurable block and taint bits from a scan chain to generate an authentication signature; and an encryptor that encrypts a test pattern response on the scan chain if a mismatch is found between the authentication signature and a test pattern embedded signature.
UP AND DOWN CONVERSION SYSTEMS FOR PRODUCTION OF EMITTED LIGHT FROM VARIOUS ENERGY SOURCES INCLUDING RADIO FREQUENCY, MICROWAVE ENERGY AND MAGNETIC INDUCTION SOURCES FOR UPCONVERSION
Methods and systems for producing a change in a medium. A first method and system (1) place in a vicinity of the medium at least one upconverter including a gas for plasma ignition, with the upconverter being configured, upon exposure to initiation energy, to generate light for emission into the medium, and (2) apply the initiation energy from an energy source including the first wavelength λ1 to the medium, wherein the emitted light directly or indirectly produces the change in the medium. A second method and system (1) place in a vicinity of the medium an agent receptive to microwave radiation or radiofrequency radiation, and (2) apply as an initiation energy the microwave radiation or radiofrequency radiation by which the agent directly or indirectly generates emitted light in the infrared, visible, or ultraviolet range to produce at least one of physical and biological changes in the medium.
H05B 41/28 - Circuits dans lesquels la lampe est alimentée par une puissance obtenue à partir de courant continu au moyen d'un convertisseur, p.ex. par courant continu à haute tension utilisant des convertisseurs statiques
A61L 2/10 - Procédés ou appareils de désinfection ou de stérilisation de matériaux ou d'objets autres que les denrées alimentaires ou les lentilles de contact; Accessoires à cet effet utilisant des phénomènes physiques des radiations des ultraviolets
A61N 1/40 - Application de champs électriques par couplage inductif ou capacitif
C02F 1/32 - Traitement de l'eau, des eaux résiduaires ou des eaux d'égout par irradiation par la lumière ultraviolette
H01J 65/04 - Lampes à atmosphère gazeuse portée à la luminescence par un champ électromagnétique extérieur ou par une radiation corpusculaire extérieure, p.ex. lampe indicatrice
98.
Methods and Compositions for the Treatment of Steatosis-Associated Disorders
The present disclosure is directed to methods of treating a steatosis-associated disorder by administering a therapeutic agent selected from a lysosomal enzyme, an autophagy-inducing agent, or a combination thereof. Steatosis-associated disorders discussed herein include GSD Ia, GSD Ib, GSD Ic, NAFLD, and NASH. Other embodiments are directed to methods of reversing steatosis, modulating autophagy, inducing autophagy, and reversing glycogen storage.
A61K 31/436 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à six chaînons ayant l'oxygène comme hétéro-atome du cycle, p.ex. rapamycine
A61K 31/216 - Esters, p.ex. nitroglycérine, sélénocyanates d'acides carboxyliques d'acides ayant des cycles aromatiques, p.ex. bénactizyne, clofibrate
A61K 31/352 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p.ex. fungichromine ayant des cycles à six chaînons avec un oxygène comme seul hétéro-atome d'un cycle condensés avec des carbocycles, p.ex. cannabinols, méthanthéline
A61K 31/167 - Amides, p.ex. acides hydroxamiques ayant des cycles aromatiques, p.ex. colchicine, aténolol, progabide ayant l'atome d'azote d'un groupe carboxamide lié directement au cycle aromatique, p.ex. lidocaïne, paracétamol
A61P 3/00 - Médicaments pour le traitement des troubles du métabolisme
A61K 31/277 - Nitriles; Isonitriles ayant un cycle, p.ex. vérapamil
A61K 31/385 - Composés hétérocycliques ayant le soufre comme hétéro-atome d'un cycle ayant plusieurs atomes de soufre dans le même cycle
A61K 31/5415 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec au moins un azote et au moins un soufre comme hétéro-atomes d'un cycle, p.ex. sulthiame condensés en ortho ou en péri avec des systèmes carbocycliques, p.ex. phénothiazine, chlorpromazine, piroxicam
A61K 31/55 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines ayant des cycles à sept chaînons, p.ex. azélastine, pentylènetétrazole
A61K 31/575 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrène; Leurs dérivés, p.ex. stéroïdes substitués en position 17 bêta par une chaîne d'au moins trois atomes de carbone, p.ex. cholane, cholestane, ergostérol, sitostérol
The present disclosure describes, in part, a Micro-organosphere immune-oncology assay and methods of making and using same. The assay quickly measures the potency of effector immune cells, such as tumor infiltrating lymphocytes, at killing a patient's tumor cells. Understanding the potency of effector immune cells is critical for adoptive T cell therapy.
G01N 33/50 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique
A61K 35/17 - Lymphocytes; Lymphocytes B; Lymphocytes T; Cellules tueuses naturelles; Lymphocytes activés par un interféron ou une cytokine
Disclosed herein are designs and implementations of a suite of novel molecular mechanisms that leverage programmable, competitive hybridization and strand displacement of nucleic acids to effectively suppress the generation of nonspecific reaction products (i.e., false positives) in molecular detection, transduction, and isothermal amplification of DNA or RNA targets. Some of the mechanisms described herein may also be applied to enhance the performance of thermocycling-based amplification methods.
C12Q 1/6848 - Réactions d’amplification d’acides nucléiques caracterisées par les moyens d’empêcher la contamination ou d’augmenter la spécificité ou la sensibilité d’une réaction d’amplification
brevets
